Theratechnologies Price to Free Cash Flow Ratio 2011-2021 | THTX

Historical price to free cash flow ratio values for Theratechnologies (THTX) since 2011. For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Theratechnologies Price to Free Cash Flow Ratio Historical Data
Date Stock Price TTM FCF per Share Price to FCF Ratio
2021-10-15 3.52 0.00
2021-08-31 3.63 $-0.17 0.00
2021-05-31 3.52 $-0.14 0.00
2021-02-28 3.21 $-0.18 0.00
2020-11-30 2.30 $-0.18 0.00
2020-08-31 2.60 $-0.16 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.333B $0.066B
Theratechnologies, Inc. is a pharmaceutical company focusing on the development of therapeutic peptide products with an emphasis on growth-hormone releasing factor peptides. It's main product EGRIFTA is used for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy which is marketed primarily in the United States, Latin America, Africa, the Middle East, Europe, Russia, South Korea, Taiwan, and Thailand. Theratechnologies, Inc. is headquartered in Montreal, Canada.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.683B 8.63
Bio-Rad Laboratories (BIO.B) United States $21.975B 46.83
QIAGEN (QGEN) Netherlands $11.773B 19.94
Biohaven Pharmaceutical Holding (BHVN) United States $8.738B 0.00
Emergent Biosolutions (EBS) United States $2.722B 6.57
Arcus Biosciences (RCUS) United States $2.455B 0.00
Myovant Sciences (MYOV) United Kingdom $1.915B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.755B 0.00
Zymeworks (ZYME) Canada $1.208B 0.00
Ambrx Biopharma (AMAM) United States $0.470B 0.00
SQZ Biotechnologies (SQZ) United States $0.342B 0.00
Enzo Biochem (ENZ) United States $0.183B 18.00